Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,267.84 -39.17 (-0.74%) Dow
39,065.26 -605.78 (-1.53%) Nasdaq
16,736.03 -65.51 (-0.39%) Bitcoin USD
68,048.16 -1,479.97 (-2.13%) CMC Crypto 200
1,458.96 -43.70 (-2.91%)
AMGN Oct 2024 220.000 call
- Zacks
Top Stock Reports for Apple, Mastercard & Amgen
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Mastercard (MA) and Amgen (AMGN), as well as two micro-cap stocks Utah Medical Products, Inc. (UTMD) and Bridger Aerospace Group Holdings, Inc. (BAER).
- Benzinga
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at
- Zacks
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
